Targeting Androgen Receptor in Breast Cancer: Enzalutamide as a Novel Breast Cancer Therapeutic
Abstract
Enzalutamide has clinical activity in breast cancer as a single agent and in combination with exemestane. Activity is seen in both triple negative AR+ BC and also ER+AR+ BC. Clinical data in Her2+ AR+ BC is too immature to make conclusions. The proposed clinical trials for Years 3-8 are justified based on clinical activity and the current preclinical data.
Document Details
- Document Type
- Technical Report
- Publication Date
- Sep 01, 2022
- Accession Number
- AD1191041
Entities
People
- Anthony D Elias
Organizations
- University of Colorado Boulder